InKemia IUCT Group successfully closes €2.5-millions capital increase

By Biocat

The first capital increase InKemia IUCT Group has carried out since going public on the Alternative Stock Market (MAB), valued at €2.5 millions, has just closed after opening in late June with excess demand of 4%. This consisted of 2,618,334 new shares at €0.95, which were purchased mainly by small shareholders “that believe in the company’s potential for growth,” according to Dr. Josep Castells, executive president of the biotechnology group.

In the coming months, InKemia will implement its strategic international expansion and growth plan. The planned investments aim to boost:

• Internationalization: reinforcing the strategy of international expansion with more intensive models and direct presence in emerging and highly technological markets. In the first stage, they will prioritize Brazil, Colombia, France and the United States. InKemia currently has subsidiaries in Colombia and agreements with companies in Japan, Brazil, Argentina and Poland.

• Pipeline: reinforcing the strategic lines of technology development and commercialization that allow for quicker launch to market.

• Knowledge Capital Fund: devoting additional resources to this fund to launch new spin-offs or participate as equity partners in new technology-based companies that generate synergies with InKemia’s main activity. Through this program, the aim is to hold equity in early-stage companies, at a rate of at least two per year, contributing both capital and knowledge. So far, the company has closed agreements with Plasma Biotech, in which it holds 19.6%, Phyture Biotech, with 21% and Enemce Pharma, with 1%.

Related news (25 March 2013)